Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Emergent BioSolutions awarded $3.8 million to develop anthrax immune globulin therapeutic

Emergent BioSolutions has announced that it has been awarded two grants from the National Institute of Allergy and Infectious Diseases (NIAID) totaling $3.8 million to support the development of the company's anthrax immune globulin (AIG) therapeutic product.

1 Sep 2006

Morphotek granted two European technology patents

Morphotek has announced that the European Patent Office has given a "Decision of Grant" regarding the Company's US Patent 6,921,666 entitled "Methods for Generating Hypermutable Yeast" and US Patent 6,737,268 entitled "A Method for Generating Genetically Altered Antigens."

30 Aug 2006

Cigarette smoking appears to promote the consumption of alcohol

Nicotine can reduce blood alcohol concentrations (BACs) at dosage levels that could be achieved by human smokers.

25 Jul 2006

Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents

By combining the properties of inorganic and organic molecules in one material, researchers at the Carolina Center of Cancer Nanotechnology Excellence (CCNE) have developed a new class of nanomaterials that can be used to create multifunctional nanoparticles.

10 Jul 2006

Chlorhexidine decreases risk of acquiring hospital-related ventilator-associated pneumonia

Researchers found that administering the topical antiseptic chlorhexidine to critically ill patients on mechanical ventilation greatly decreased their daily risk of acquiring deadly hospital-related ventilator-associated pneumonia.

18 Jun 2006

The science of sex and gender in human health

The National Institutes of Health (NIH) Office of Research on Women's Health (ORWH), in collaboration with the Food and Drug Administration (FDA) Office of Women's Health (OWH), have announces the launch of a new online course, "The Science of Sex and Gender in Human Health."

5 Jun 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

Neuren granted US patent for NNZ-2566

Neuren Pharmaceuticals has announced that its patent application entitled "GPE Analogs and Peptidomimetics" (PCT/US02/16361) has been issued in the United States (US Patent No: 7,041,314) on 9 May 2006.

10 May 2006

Peptide for myocardial infarction proves to be safe

FIBREX Medical has successfully completed a first dose in man study with its lead product, the anti-inflammatory peptide FX06.

6 Apr 2006

Injection of EU funds for a microdose project

A new EU-funded project kicked off this month which aims to bridge the gap between the laboratory and the clinic. The EU Microdose AMS Partnership Programme (EUMAPP) aims to boost Europe’s expertise in micodosing and its application of AMS, or accelerator mass spectrometry, to developing new candidate drugs for treating diseases the world over.

23 Jan 2006

First clinical study of FX06 treatment against damage caused by heart attacks

Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.

7 Nov 2005

New treatment for the pediatric eye cancer retinoblastoma

Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.

17 Oct 2005

Myriad Genetics nears completion of antithrombin drug trial

Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.

11 Oct 2005

Data show that HIV-infected older people not taking HAART have double the risk of death

HIV is often regarded as a disease of young people, due to its status as a drug-related or sexually transmitted disease. However, the number of people over age 50 who are infected with HIV is significant--and growing--according to an article in the Sept. 15 issue of Clinical Infectious Diseases, now available online.

30 Aug 2005

Lorus identifies novel class of lead drug candidates from small molecule anticancer program

Lorus Therapeutics has announced the continued success in the development of its small molecule anticancer program with the selection of a sub-class of lead molecules from the Company's small molecule program.

24 Aug 2005

Firefly protein lets researchers monitor molecule known as IKK (for IKappa kinase) linked to cancer

Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.

9 Aug 2005

Genelabs drug discovery team advances compounds against the hepatitis C virus

Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.

4 Aug 2005

Analysis of the Phase I/II clinical trial of HIV drug candidate PA-457

V.I. Technologies (Vitex) and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil.

26 Jul 2005

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Human Genome Sciences has announced that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin

19 Jul 2005

Fine tuning drug levels in neuroblastoma patients is effective

Monitoring and fine tuning the levels of the cancer drug topotecan in children with neuroblastoma holds promise for maximizing the drug's effectiveness while reducing its toxicity, according to investigators at St. Jude Children's Research Hospital.

19 Jun 2005